SPARC, a company in the Pharmaceuticals industry, reported revenue of ₹30 crore and a net loss of ₹25 crore for the September 2026 quarter.
SPARC (NSE: SPARC) closed at ₹190.16 on 20 Nov 2026, up 37.7% over the past year. Its market capitalisation is ₹6,171 crore and it trades at 3.8 times earnings.
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.